Pathos AI Closes $62M Oversubscribed Series C Round of Financing to Accelerate its Platform Approach to Drug Development
CHICAGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Pathos AI, (www.pathos.com), a clinical-stage biotechnology company focused on re-engineering drug development through artificial intelligence, today announced the closing of an oversubscribed $62M Series C funding round. The Series C financing round was...
Read More
Pathos Expands Pipeline With Worldwide License of Phase 2-ready Program, a Brain-penetrant, PRMT5 Inhibitor
Chicago – Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug development, announced today the world-wide license of PRT811, a potent, selective, and orally bioavailable...
Read More
Pathos AI Completes Acquisition of Rain Oncology
Rain Stockholders to Receive $1.16 Per Share in Cash Plus Contingent Value Rights CHICAGO--(BUSINESS WIRE)--Pathos AI, Inc. (www.pathos.com), today announced that it has, through its wholly owned subsidiary WK Merger Sub, Inc. (“Merger Sub”), successfully completed its tender offer to...
Read More
Pathos Launches Precision Oncology Pipeline With License of First Phase I Program, a CBP/p300 Inhibitor
Pathos obtains worldwide rights from Novo Nordisk for the development of CBP/p300 inhibitor, FT-7051 Chicago – Pathos AI, Inc. (www.pathos.com), a biotechnology company focused on revolutionizing precision medicine in cancer by harnessing the power of machine learning to transform drug...